Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2004

View Archived Issues

Rosiglitazone inhibits keratinocyte proliferation

HMG-CoA reductase mediates the anticortisol effect of procaine

Novel CCK2B selective agonist with original pharmacological properties described

NHE exchanger inhibitor SM-20220 protective against excitotoxicity

Ampligen protects against coxsackie B3 virus-induced myocarditis

Acambis restructures and reprioritizes

Novel DPP-IV inhibitors under study at Sanofi-Synthelabo

U. of Tennessee researchers design new selective androgen receptor modulators

New 5-HT2C agonists for obesity and other disorders covered by Biovitrum patent

BMS team prepares and tests new anti-HIV agents

Aniline-based factor VIIa inhibitors newly identified at BMS

Two series of protein kinase modulators patented by Cellular Genomics

Takeda describes new prodrugs of proton pump inhibitors and their use

Sanofi-Synthelabo claims novel TNF-alpha production inhibitors for inflammation and pain

Bayer to distribute Testim in Canada

Shareholder approval of Genome Therapeutics/Genesoft merger

BioSante updates development progress

Registrational satraplatin trial expanded into Europe

Xcel acquires retigabine rights from Viatris

Caduet receives FDA approval

Roche and AEterna enter Brazilian marketing agreement for Impavido

Roll-out of Zyprexa

Positive preclinical results for GLP1-I.N.T

Treatment completed in phase II FM-VP4 trial

Development status of Arius antibodies

Bone Care International reports very productive Q2 FY2004

Altana sustains growth throughout 2003

Unacceptable safety profile found for HRT in breast cancer survivors

A phase II clinical trial shows no effects for repifermin in cancer therapy-induced mucositis

OrthoLogic continued progress with Chrysalin product platform during the past year

Merck & Co. highlights efforts to drive long-term growth in 2003

Cell Genesys reports developments of lead product candidate GVAX over past year

Kissei obtains marketing approval of Glufast in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...